CA3211203A1 - Methods and materials for treating clonal t cell expansions - Google Patents

Methods and materials for treating clonal t cell expansions Download PDF

Info

Publication number
CA3211203A1
CA3211203A1 CA3211203A CA3211203A CA3211203A1 CA 3211203 A1 CA3211203 A1 CA 3211203A1 CA 3211203 A CA3211203 A CA 3211203A CA 3211203 A CA3211203 A CA 3211203A CA 3211203 A1 CA3211203 A1 CA 3211203A1
Authority
CA
Canada
Prior art keywords
polypeptide
antigen binding
binding domain
bind
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3211203A
Other languages
English (en)
French (fr)
Inventor
Michael S. HWANG
Kenneth W. Kinzler
Brian J. MOG
Nickolas Papadopoulos
Andrew PARDOLL
Suman PAUL
Bert Vogelstein
Shibin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA3211203A1 publication Critical patent/CA3211203A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3211203A 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions Pending CA3211203A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150232P 2021-02-17 2021-02-17
US63/150,232 2021-02-17
PCT/US2022/016423 WO2022177889A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Publications (1)

Publication Number Publication Date
CA3211203A1 true CA3211203A1 (en) 2022-08-25

Family

ID=80595091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3211203A Pending CA3211203A1 (en) 2021-02-17 2022-02-15 Methods and materials for treating clonal t cell expansions

Country Status (7)

Country Link
US (1) US20240124608A1 (enExample)
EP (1) EP4294841A1 (enExample)
JP (1) JP2024508749A (enExample)
CN (1) CN117561277A (enExample)
AU (1) AU2022222679A1 (enExample)
CA (1) CA3211203A1 (enExample)
WO (1) WO2022177889A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
JP2026524330A (ja) * 2023-06-28 2026-07-22 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｔｒｂｃ標的化抗体薬物複合体
WO2025220689A1 (ja) * 2024-04-17 2025-10-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Ｔ細胞機能不全のｔ細胞性腫瘍患者に有効な二重特異性抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2744046C2 (ru) * 2014-03-05 2021-03-02 Отолус Лимитед ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
GB201817172D0 (en) * 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain

Also Published As

Publication number Publication date
AU2022222679A1 (en) 2023-09-07
JP2024508749A (ja) 2024-02-28
WO2022177889A1 (en) 2022-08-25
CN117561277A (zh) 2024-02-13
US20240124608A1 (en) 2024-04-18
EP4294841A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
KR101997241B1 (ko) 삼중특이성 결합 단백질 및 사용 방법
ES2962260T3 (es) Proteínas de fusión SIRPa alfa-anticuerpo
CN110511278B (zh) 抗b7-h6抗体、融合蛋白及其使用方法
US20180208670A1 (en) Methods for enhancing anti-tumor antibody therapy
KR20200026810A (ko) Msln 표적화 삼중 특이적 단백질 및 사용 방법
US20240124608A1 (en) Methods and materials for treating clonal t cell expansions
US20260116971A1 (en) Antibodies specific to human nectin-2
CN109195988B (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
US20120052515A1 (en) Therapeutic applications of noncovalent dimerizing antibodies
JP2021510299A (ja) 抗体の新規組み合わせおよびその使用
WO2019075413A1 (en) DOSAGE SCHEME FOR CD3 BINDING PROTEINS
US20240156863A1 (en) Sequential anti-cd19 therapy
ES2338919T3 (es) Anticuerpos anti-receptor ccr7 para el tratamiento del cancer.
CA3173909A1 (en) Superantigen conjugate for use in methods and compositions for treating cancer
TW202426476A (zh) 用於靶向膜蛋白及貨物之內化及降解之受體介導之胞吞作用
JP2025128349A (ja) 二重特異性タンパク質
AU2020244862B2 (en) Semaphorin-4D antagonists for use in cancer therapy
JP7630435B2 (ja) 抗ｃｄ１２３免疫複合体を用いた治療法
CZ20013270A3 (cs) Protilátkové a chemokinové konstrukty a jejich pouľití při léčbě autoimunitních chorob
JP7533330B2 (ja) Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
JP2024517130A (ja) グリア芽腫を治療するための方法および組成物
US11814436B2 (en) Anti-CD30 monoclonal antibodies and chimeric antigen receptors
TW202602910A (zh) 一種雙融合蛋白及其用途
WO2025217204A1 (en) Methods and materials for treating p53+ cancers
CN118696064A (zh) 间变性淋巴瘤激酶抗体及其使用方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250620

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251028

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260206

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260210